According to Report, the in vitro fertilization test market is expected to reach a valuation of ~US$ 3 Bn by 2030.
According to Report, the in vitro fertilization test market is expected to reach a valuation of ~US$ 3 Bn by 2030.
Delay in IVF Treatments Affects Market Growth during Coronavirus Pandemic
Due to the ongoing COVID-19 pandemic, several individuals are considering delaying their in vitro fertilization (IVF) treatment. Since the IVF treatment is linked with genetic compatibility test and sperm aneuploidy test, the delay in the IVF treatment of women may lead to staggered revenue growth in the in vitro fertilization test market. In order to overcome this challenge, healthcare professionals are increasing awareness that majority of patients in the reproductive age are generally not in the high risk-group in contracting the novel infection. Such awareness is anticipated to revive the growth of the in vitro fertilization test market.
Download Sample @ https://qyresearchmedical.com/sample/111537
Telemedicine appointments for initial and follow-up consultations are further reducing the risk of contracting COVID-19 among patients, medical professionals and individuals. In case of urgent and emergency visits at fertility clinics & hospitals, facilities are taking extra precaution to install HEPA (high efficiency particulate air) filtration systems.
Solutions for Medically Complicated Patients, Simple Metrics Improve Clinical Numbers
The IVF procedure is potentially challenging in patients with pre-existing medical conditions. The IVF is a complex series of procedures involving ovarian stimulation, oocyte retrieval, and laboratory techniques to achieve maximal rates of fertilization, embryo development, and embryo transfer (ET). In order to ensure the faith of medically complicated patients, healthcare professionals are offering specific treatments to hypertension patients or patients with cardiovascular diseases. These include antihypertensive medications and regular cardiology consultation, respectively, to improve clinical outcomes in the in vitro fertilization test market.
Describing medical outcomes from in vitro fertilization test has been an evolving challenge throughout the world. This has led to the importance of three simple metrics that provide a transparent and highly accurate summary of IVF tests. These include the probability of having no embryo available to transfer, sustained implantation rate, and the number of supernumerary embryos cryopreserved during the cycle.
Customizable PGT Helps Obtain Accurate Diagnosis for Patient Embryo
The preimplantation genetic testing (PGT) is being associated with significantly reducing the chances of having a baby with a specific genetic condition or chromosomal abnormality. This is evident since the preimplantation genetic testing is predicted to dictate the highest revenue share among all test types in the in vitro fertilization test market during the forecast period. Medical laboratory Reproductive Genetic Innovations in Illinois is gaining popularity for its PGT services that can be customized to obtain the most accurate diagnosis for a patient’s embryo.
Fertility clinics and hospitals in the in vitro fertilization test market are on-boarding scientists and genetic counselors that work with the patient’s physician to determine the optimal testing plan for each individual case. Such testing strategies help to determine which biopsy test will be recommended.
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111537/2900
Preference for PGT-A to Improve Implantation Rates, Reduce Miscarriages
The in vitro fertilization test market is expected to reach a valuation of ~US$ 3 Bn by 2031. Based on claims of better live birth and reduced miscarriage rates, the technique of the preimplantation genetic testing for aneuploidy (PGT-A) in association with IVF has increasingly grown in the U.S. Companies in developing economies of South Asia are taking cues from such findings to improve their medical services in hospitals and fertility clinics.
PGT-A in a single trophectoderm biopsy at blastocyst stage reliably determines whether an embryo is euploid or chromosomal abnormal. PGT-A is gaining recognition in the in vitro fertilization test market for improving implantation rates and reducing miscarriages. This strategy has now become a routine add-on for IVF to determine whether human embryos are to be clinically utilized or disposed.
Analysts’ Viewpoint
Digital consultation and counselling are growing prominent in healthcare facilities during the coronavirus outbreak to minimize patient visits and avoid the novel infection. The Clomid challenge test is gaining increased popularity, and it is performed before the start of the IVF treatment. However, it is found that the test is either inconclusive or less reliable than other ovarian reserve tests. Hence, companies in the in vitro fertilization test market should increase awareness about PGT-A and the three simple metrics that help to improve clinical numbers and provide a highly accurate summary of ovarian reserve tests. PGT-A helps to reduce miscarriages and improve implantation rates.
In Vitro Fertilization Test Market: Overview
This report analyzes the current and future prospects of the global in vitro fertilization test market. Increase in population with infertility issues, in vitro fertilization success rates, inclination toward delayed pregnancies, number of fertility clinics across the globe, and fertility tourism is a key factor projected to fuel the growth of the global in vitro fertilization test market during the forecast period.
The report provides an elaborate executive summary, which comprises a snapshot of the various segments of the global in vitro fertilization test market. The report also provides information and data analysis of the global in vitro fertilization test market about segments based on test type, end user, and region.
The overview section of the report provides detailed qualitative analysis of drivers and restraints impacting the global in vitro fertilization test market, along with opportunities in the global market
Additionally, the global in vitro fertilization test market report includes company profiles and competitive matrix, which provide data about their businesses, product portfolios, and competitive landscape in the global in vitro fertilization test market
The report includes data analysis on the in vitro fertilization test market attractiveness by region and segments
The last section of the report provides quantitative and qualitative analysis on market share of key players operating in the global in vitro fertilization test market. It elaborates on the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global in vitro fertilization test market.
In Vitro Fertilization Test Market: Key Segments
In terms of test type, the global in vitro fertilization test market has been classified into sperm aneuploidy test, genetic compatibility test, preimplantation genetic testing, endometrial receptivity analysis, noninvasive prenatal testing, and others
The preimplantation genetic testing segment held a major share of the global in vitro fertilization test market in 2020
Based on end user, the global in vitro fertilization test market has been divided into fertility clinics, hospitals, and others. The fertility clinics segment is anticipated to lead the global in vitro fertilization test market during the forecast period.
The market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year.
In Vitro Fertilization Test Market: Regional Outlook
In terms of region, the global in vitro fertilization test market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa)
The report provides market size and forecast for each region and country/sub-region from 2017 to 2031. Compound annual growth rate (CAGR) of each of these regions and countries have also been provided for the forecast period from 2021 to 2031, considering 2020 as the base year. The in vitro fertilization test market study also covers the competitive scenario in these regions.
Companies Mentioned in Report
Key players in the global in vitro fertilization test market have been profiled based on key aspects such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
Major companies profiled in the global in vitro fertilization test market report are
- CooperSurgical, Inc.
- Esco Micro Pte Ltd.
- FUJIFILM Irvine Scientific
- Hamilton Thorne, Inc.
- Vitrolife AB
- IVFtech ApS
- Nidacon International AB
- Igenomix
- Thermo Fisher Scientific
- Cook
- Genea Biomedx
- FertiPro N.V
- Kitazato Corporation
- PerkinElmer, Inc.
- Natera
- Takara Bio, Inc.
- iGLS
- CiceroDx
Key Questions Answered in In Vitro Fertilization Test Market Report
- How does the development of in vitro fertilization tests provide scope of growth in the global in vitro fertilization test market?
- How alliances and partnerships among players are widening the scope of new line of technologies for in vitro fertilization test?
- What are the revenue share projections of key segments under various criteria in the in vitro fertilization test market during the forecast period?
- Which segment is likely to register highest revenue until the end of the forecast period in 2031?
- How is the evolving healthcare system in developing countries in Asia Pacific making an impact on the overall in vitro fertilization test market?
In Vitro Fertilization Test Market – Segmentation
Test Type
- Sperm Aneuploidy Test
- Genetic Compatibility Test
- Preimplantation Genetic Testing
- Endometrial Receptivity Analysis
- Noninvasive Prenatal Testing
- Others
End User
- Fertility Clinics
- Hospitals
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111537/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/